On August 30, 2017, the FDA approved the first US CAR-T cell therapy for the treatment of ALL patients. According to FDA Commissioner Dr. Scott Gottlieb, “We’re entering a new frontier in medical innovation with the ability to reprogram a patient’s own cells to attack a deadly cancer.” Check out this brief video about how CAR-T cell therapy works.
At StemExpress we offer human blood products such as whole blood and leukopaks as well as peripheral blood CD3+, CD4+, and CD8+ T cells. Purified primary CD3+, CD4+, and CD8+ T cells are a timely source and cost-effective means of obtaining cells for use in CAR-T cell research studies. All blood collections follow IRB approved consents and protocols.
Contact one of our sales specialists at 530-303-3828 to discuss the specific needs of your project or fill out our Contact form for additional information.
Follow us on LinkedIn to keep up-to-date on exciting trends, promotions, and new product releases.